Search
HomeBiointelect VenturerOur Governance

Our Governance

Biointelect Venturer is underpinned by a strong governance framework and transparent decision-making processes.

Biointelect Venturer operates under the oversight of the Biointelect Board and within a robust governance framework that ensures independence, accountability and transparency.

The strategic direction of Biointelect Venturer is guided by advice from the Steering Committee, Funding Investment Panel, and Consumer Advisory Group. The SME application review, assessment and selection process is undertaken by the Investment Review Committee (IRC) – an independent panel of nationally and internationally recognised experts.  The Steering Committee reviews and endorses application recommendations for consideration and approval by the Biointelect Board.

All governance processes are underpinned by principles of independence, transparency, accountability, integrity, diversity and inclusion, and continuous improvement.

Operation and Management Team

Strategic Advisor

Strategic Project Manager

Biointelect Venturer Steering Committee

The Steering Committee is an independent, nationally representative advisory group that provides expert advice on the establishment and operation of the incubator, and oversight of SME applicant selection.

Biointelect Venturer Panel Experts

The Biointelect Venturer Investment Review Panel comprises a distinguished pool of nationally and internationally recognised leaders who are engaged across the Venturer program to support rigorous, independent funding and investment decisions.

The Panel includes individuals with contemporary, domain-specific expertise spanning vaccine and immunotherapy development, infectious diseases, pre-clinical and clinical translation, regulatory affairs, manufacturing and CMC, intellectual property, investment and commercialisation. Collectively, these experts bring deep technical and market insight to the evaluation process.

For each assessment round, a selection of panellists is appointed to form an Investment Review Committee to support the Expression of Interest, Full Applicant review and assessment process, as well as due diligence and interview processes. This ensures projects are assessed with scientific depth, commercial realism and a strong focus on translation to impact.

All experts operate under strict confidentiality and Conflict-of-Interest policies, safeguarding the integrity, transparency and independence of Biointelect Venturer’s decision-making framework.

Allan Saul

Expert Advisor / Investment Review Panel Member

John Skerritt

Investment Review Panel Member

Steve Rockman

Investment Review Panel Member

Lisa Bonadonna

Investment Review Panel Member

Chris Blyth

Investment Review Panel Member

Felicia Pradera headshot
Felicia Pradera

Investment Review Panel Member

Paul Young

Investment Review Panel Member

Tony Cunningham

Investment Review Panel Member

Patrick James

Investment Review Panel Member

Mathias Kroll

Investment Review Panel Member

Gary Grohmann

Investment Review Panel Member

Danielle Shand

General Manager, Biointelect Venturer

Danielle Shand has over 20 years’ experience in the pharmaceutical and medtech sectors, including seven years leading national programs and initiatives that connect industry, research, and Australia’s broader innovation ecosystem.

Prior to joining Biointelect, Danielle held senior leadership roles at MTPConnect, where she led and managed teams to deliver more than $43 million in Medical Research Future Fund (MRFF) investment through the Biomedical Translation Bridge (BTB) and Clinical Translation and Commercialisation (CTCM) Medtech Accelerator programs. She oversaw the strategic planning, governance, and operations of these national initiatives, supporting 33 funded projects, advancing 65 Australian medtech and pharmaceutical technologies, and generating significant follow-on investment across the MTP sector.

Danielle brings expertise in program delivery, governance, grants management, strategic planning, and financial oversight, with 13 years’ earlier experience at Pfizer.

Danielle joined Biointelect in 2026 and is based in Sydney, where she serves as General Manager of Biointelect Venturer. In this role, she leads the strategic design and delivery of the federally funded incubator, supporting emerging companies and academic innovators to advance vaccine and related technologies toward investment and commercial readiness.

Leanne Hobbs

General Manager

With 30 years of experience in the biotech, vaccine, and pharmaceutical industries across both local and international landscapes, Leanne is a highly respected leader in product development and commercialisation strategy. Formerly CEO Sementis Ltd and as Global Senior Executive at GSK Vaccines, Leanne has led diverse teams in developing and commercialising vaccines and medical technologies across a wide range of disease areas, geographies, and investment levels. She also contributes her expertise as a Board Commercialisation Committee Member at WEHI (Walter and Eliza Hall Institute of Medical Research) and mentor to several biotechnology start-ups, helping guide strategic decisions to support translation of cutting-edge research into impactful medical solutions.

With an extensive global network, Leanne connects local scientists and businesses with the right expertise at the right time. She has been deeply engaged in the start-up ecosystem locally and internationally as a pitch judge, mentor, and expert advisor, with broad experience in incubator and mentoring programs and a deep understanding of what makes successful products, teams and companies. Passionate about fostering innovation and economic growth, she is committed to making a meaningful impact by helping bring life-changing technologies to the people who need them most.

Leanne Hobbs is a Strategic Advisor to Biointelect Venturer, following her foundational leadership as the program’s inaugural General Manager. She continues to guide strategic direction, ecosystem engagement, and partnership development for the incubator.

Lena Miloradovic

Strategic Project Manager

Lena Miloradovic brings over 30 years of project management and operational experience in the biotech industry. She holds a Bachelor of Biological Science from La Trobe University and is a certified Project Management Professional (PMP)® by the Project Management Institute USA. Her extensive expertise encompasses managing complex projects in vaccine development and establishing efficient quality management systems. 

Early in her career, Lena joined CSL Research and Development (R&D) to manage the development of vaccines. Her roles included working with small biotech companies in R&D product development, program management, and the establishment of quality management systems. Her operational experience, covering manufacturing and quality aspects, provided a solid foundation for managing late-stage R&D vaccine development projects. This included overseeing the internationalisation of BioCSL influenza vaccines in the United States and Europe and leading product development studies and clinical trials for early-stage vaccines.  

Lena joined Biointelect in 2021 as the Project Manager for the Novavax COVID-19 Vaccine. In this pivotal role, she provided support to Biocelect as the local sponsor, collaborating closely with cross-functional teams and international and local stakeholders to facilitate the introduction of this vaccine to the Australian and New Zealand populations during the COVID-19 pandemic. She also provided strategic project management support to the University of Melbourne and Doherty Institute collaboration on a COVID-19 vaccine candidate for Phase 1 clinical study. 

Dr Greiciely André

SME Project Manager

Dr. Greiciely André brings over 10 years of experience in translational research, vaccine development, and project delivery across academic and industry settings. She holds a PhD in Molecular and Cellular Biology focused on vaccine development and has led early phase vaccine programs from discovery through to human clinical trials. She has managed cross functional teams and development contracts valued at more than USD$20million, including major awards funded by the US National Institutes of Health (NIH).

A key achievement in her career includes contributing to the development and Emergency Use Authorization of the SpikoGen® COVID 19 vaccine, the first recombinant protein vaccine to reach this milestone, and its AI designed adjuvant, an early example of an AI guided component incorporated into a licensed human vaccine. Her expertise also spans preclinical research, GMP manufacturing, clinical trials, and regulatory compliance, enabling her to bridge scientific innovation with operational and commercial execution.

Dr. Greiciely joined Biointelect Venturer in 2026, where she supports emerging companies and academic innovators in progressing infectious disease technologies toward investment and commercial readiness. As a SME Project Manager, she leverages her technical and operational expertise to guide SMEs through translation pathways, contributing to the Biointelect Venturer incubator’s mission of accelerating breakthrough vaccine and related technologies.

Prof. Trent Munro

Director, University of Queensland

  • Completed a PhD in Protein Biochemistry from UQ and completed postdoctoral studies in cell biology and developmental genetics at the Department of Cell Biology, Harvard Medical School and at the Wellcome Trust and Cancer Research UK Gurdon Institute, University of Cambridge.
  • Director of the NCRIS-funded National Biologics Facility (NBF)
  • Program Director for CEPI’s Rapid Response Vaccine Pipeline
  • Former Executive Director of Process Development at Amgen Inc.
  • Led a global team of ~90 staff at Amgen, driving molecule translation from research to commercial launches
  • Extensive expertise in establishing developability criteria for new therapeutic agents
  • Experienced in design and production of various therapeutics, including monoclonal antibodies and cellular therapies
  • Published extensively on therapeutic product design and production
  • Developed novel approaches to shorten timelines from candidate identification to clinical evaluation
  • Significant experience in pre-clinical and clinical development of complex therapeutic agents

Prof. Margie Danchin

Royal Children’s Hospital

  • A paediatrician, vaccinologist and Dame Kate Campbell Fellow at the Royal Childrens Hospital, University of Melbourne and Murdoch Childrens Research Institute (MCRI) and Associate Dean International for the Faculty of Medicine, Dentistry and Health Sciences (MDHS), University of Melbourne.
  • As leader of the Vaccine Uptake and Clinical trials Group, MCRI, her research focuses on vaccine effectiveness, safety, confidence and uptake, particularly amongst priority populations and in low resource settings, and on effective risk communication. In Australia, she is a member of the Australian Technical Advisory Group on Immunisation (ATAGI) and chair of the Social Science Advisory Board and a member of the Scientific Advisory Committee, National Centre for Immunisation Research and Surveillance (NCIRS). Her research has significantly influenced immunisation policy and practice in Australia and globally. She has secured over $50 million in research funding and authored more than 190 publications. She is committed to efforts to improve child health and vaccine confidence and uptake globally and in the Asia Pacific Region and works closely with DFAT to provide technical immunisation support for the region. She is passionate about effective science communication, working closely with the media to communicate about child health issues and vaccines.
  • Awards received: PHAA President’s award (2022); BioMelbourne Network Women in Leadership award for Innovation and impact during the pandemic (2021); Churchill Fellowship (2020) to access global expertise to improve COVID-19 and routine vaccine uptake

Dr Jeff Davies

Co-Founder & Director, Centre for Biopharmaceutical Excellence

  • Senior executive with over 35 years of experience in the biopharmaceutical industry
  • Founding director of CBE established (2014) and CBE Pure Solutions (2021)
  • Experience providing consulting and training services to the pharma and biopharmaceutical industry, including early-stage SMEs in areas such as vaccines
  • Experience providing services to support Phase 1 and 2 clinical trials as Director of a contract manufacturing organization
  • Expertise in investment opportunities, general strategy, R&D portfolios, organizational design, regulatory matters, product development, and clinical strategies
  • Senior executive management positions at CSL with oversight of plasma products, influenza vaccines, anti-venoms, licensed vaccines and pharmaceuticals, as well as the diagnostic product business
  • Major role in project selection and leadership of Global Plasma Product R&D programs from inception through to commercialization

Erica Bremner Kneipp

Research Director, Human Health, CSIRO

  • 30+ years of senior executive public policy leadership in health and medicine across government and research institutes
  • Led major research infrastructure initiatives, – $20 billion Medical Research Future Fund (MRFF) and $500+ million Biomedical Translation Fund
  • Expertise in healthcare data, pricing and system funding, public-private partnerships, and clinical trial and primary care reform
  • Currently manages CSIRO’s Human Health program, focusing on infectious disease prevention, preparedness and response
  • Experienced in leading large research teams, with diverse capabilities and driving post-COVID recovery in science programs
  • Strong strategic, stakeholder and government relations skills with influential public and private sector networks
  • Non-Executive Director roles with Brandon BioCatalyst, AusBiotech, and BioPlatforms Australia

Mitchell Hartman

Chief of Staff, Telethon Kids Institute

  • Strategic executive leader with a medical background and nearly a decade of governance experience across healthcare, research, and not-for-profit sectors.
  • Currently Chief of Staff at Kids Research Institute Australia, he drives organisational strategy, stakeholder engagement, and complex project delivery. His experienced in healthcare innovation, product development and change to drive impact.
  • Significant governance experience across multiple sectors including public health, health and aged care, NDIS and life sciences.

Camille Shanahan

General Manager, Jumar Incubator

  • Extensive management, leadership and business development experience in biosciences
  • Biotech Incubator management experience with start-up and operational experience at Jumar Bioincubator
  • Experienced across clinical, scientific, business development and commercialisation roles in the biopharma sector, working in Australia and Canada
  • Built on her academic medical research experience to facilitate the translation of Australia’s world-class research into clinical solutions
  • Strong track record in managing projects in early stage translational, STEM infrastructure and health policy
  • Worked in life sciences consulting and business development roles developing strong ties with biotech companies at all stages of product development and with key peak bodies
  • Network: biotech/pharma, government, biomedical research, consultants, start-ups, venture capital, IP
  • Clinical Experience: 8 years as an orthotist, in hospitals and private clinics

Dr. Martin Elhay

Business Development, Peter Doherty Institute, The University of Melbourne

  • 20+ years of experience in research and management in the biotechnology, human and animal health sectors in Australia and Europe
  • Completed a PhD in Immunology from the Walter and Eliza Hall Institute of Medical Research (WEHI) on a parasitic disease Leishmaniasis
  • Active in the Australian and international vaccine and adjuvant community
  • Inventor on two technology patents, including one for a vaccine against the Hendra virus developed with the Henry Jackson Foundation and CSIRO
  • Product development and senior scientific experience at CSL and then at Pfizer. Led product development teams developing vaccines for livestock and companion animals
  • At Pfizer, responsible for assessment and valuation of novel technologies from university and private industry partners, development of new technology partnerships and extension of Pfizer’s portfolio into the Asia Pacific region
  • Seconded (2020) to the Peter Doherty Institute for Infection and Immunity to support their research activities and facilitate industry interactions

Eri Nishiuchi

Strategic Development and Business Effectiveness

Eri Nishiuchi holds a Bachelor of Business degree from the University of Technology Sydney. Her expertise lies in health systems analysis and client relationship management within the healthcare and life sciences sectors. She also has experience working with patient organisations.

Throughout her career, Eri has provided competitive landscape research support to pharmaceutical and biotech clients across the Asia Pacific region, achieving one of the top client retention rates in the region. Her multilingual abilities have been instrumental in fostering strong relationships with diverse stakeholders.

Eri joined Biointelect in 2024 in a strategic development and business effectiveness role, where her focus will be on conducting market analysis and improving business processes.